Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Prescription Trends of SGLT2 Inhibitors (2023), by Region
5.2 Production and Usage Volume of SGLT2 Inhibitor Drugs (2020–2023)
5.3 Healthcare Spending on SGLT2 Inhibitors (2023)
5.4 Regulatory Approvals and Clinical Trial Trends (2020–2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. SGLT2 Inhibitors Market Segmentation By Indication
7.1 Chapter Overview
7.2 Chronic Kidney Disease (CKD)
7.2.1 Chronic Kidney Disease (CKD) Market Trends Analysis (2021-2032)
7.2.2 Chronic Kidney Disease (CKD) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Type 2 Diabetes
7.3.1 Type 2 Diabetes Market Trends Analysis (2021-2032)
7.3.2 Type 2 Diabetes Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Cardiovascular
7.4.1 Cardiovascular Market Trends Analysis (2021-2032)
7.4.2 Cardiovascular Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Others
7.5.1 Others Market Trends Analysis (2021-2032)
7.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. SGLT2 Inhibitors Market Segmentation By Drug
8.1 Chapter Overview
8.2 Jardiance (Empagliflozin)
8.2.1 Jardiance (Empagliflozin) Market Trend Analysis (2021-2032)
8.2.2 Jardiance (Empagliflozin) Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Inpefa (Sotagliflozin)
8.3.1 Inpefa (Sotagliflozin) Market Trends Analysis (2021-2032)
8.3.2 Inpefa (Sotagliflozin) Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Farxiga (Dapagliflozin)
8.4.1 Farxiga (Dapagliflozin) Market Trends Analysis (2021-2032)
8.4.2 Farxiga (Dapagliflozin) Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Invokana (Canagliflozin)
8.5.1 Invokana (Canagliflozin) Market Trends Analysis (2021-2032)
8.5.2 Invokana (Canagliflozin) Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Qtern (Dapagliflozin/Saxagliptin)
8.6.1 Qtern (Dapagliflozin/Saxagliptin) Market Trends Analysis (2021-2032)
8.6.2 Qtern (Dapagliflozin/Saxagliptin) Market Size Estimates and Forecasts to 2032 (USD Billion)
8.7 Others
8.7.1 Others Market Trends Analysis (2021-2032)
8.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. SGLT2 Inhibitors Market Segmentation By Distribution Channel
9.1 Chapter Overview
9.2 Hospital Pharmacies
9.2.1 Hospital Pharmacies Market Trends Analysis (2021-2032)
9.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Retail Pharmacies
9.3.1 Retail Pharmacies Market Trends Analysis (2021-2032)
9.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Online Pharmacies
9.4.1 Online Pharmacies Market Trends Analysis (2021-2032)
9.4.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America SGLT2 Inhibitors Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.2.4 North America SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.5 North America SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.2.6.2 USA SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.6.3 USA SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.2.7.2 Canada SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.7.3 Canada SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.2.8.2 Mexico SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.8.3 Mexico SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe SGLT2 Inhibitors Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.4 Europe SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.5 Europe SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.6 Germany
10.3.6.1 Germany SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.6.2 Germany SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.6.3 Germany SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.7.2 France SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.7.3 France SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.8.2 UK SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.8.3 UK SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.9.2 Italy SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.9.3 Italy SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.10.2 Spain SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.10.3 Spain SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.11 Poland
10.3.11.1 Poland SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.11.2 Poland SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.11.3 Poland SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.12 Turkey
10.3.12.1 Turkey SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.12.2 Turkey SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.12.3 Turkey SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.13 Rest of Europe
10.3.13.1 Rest of Europe SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.3.13.2 Rest of Europe SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.13.3 Rest of Europe SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.4 Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.5 Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.6.2 China SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.6.3 China SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.7.2 India SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.7.3 India SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.8.2 Japan SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.8.3 Japan SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.9.2 South Korea SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.9.3 South Korea SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.10.2 Singapore SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.10.3 Singapore SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.11.2 Australia SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.11.3 Australia SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.12 Rest of Asia Pacific
10.4.12.1 Rest of Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia Pacific SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa SGLT2 Inhibitors Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.5.4 Middle East and Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.5 Middle East and Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.5.6.2 UAE SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.6.3 UAE SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.5.8.2 Qatar SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.8.3 Qatar SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9.1 South Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.5.9.2 South Africa SGLT2 Inhibitors Market Estimates and Forecasts By Drug (2021-2032) (USD Billion)
10.5.9.3 South Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America SGLT2 Inhibitors Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.6.4 Latin America SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.5 Latin America SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.6.6.2 Brazil SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.6.3 Brazil SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.6.7.2 Argentina SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.7.3 Argentina SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America SGLT2 Inhibitors Market Estimates and Forecasts, By Indication (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America SGLT2 Inhibitors Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America SGLT2 Inhibitors Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
11. Company Profiles
11.1 Boehringer Ingelheim International GmbH
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2 Sanofi
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 AstraZeneca
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 TheracosBio, LLC
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 Merck & Co., Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 TheracosBio, LLC
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 Glenmark Pharmaceuticals Ltd.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 Lexicon Pharmaceuticals, Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 Eli Lilly and Company
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 Johnson & Johnson Services, Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion